Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trialThierry Conroy, Jean‐Baptiste Bachet, Christelle de la Fouchardière et al.|The Lancet Oncology|2021Cited by 1.3k
Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal CancerJean‐Pierre Gérard, Thierry Conroy, D. Azria et al.|Journal of Clinical Oncology|2012Cited by 431
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trialThierry Conroy, Christophe Borg, Florence Castan et al.|Annals of Oncology|2024Cited by 187
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.Thierry Conroy, Christophe Borg, Najib Lamfichekh et al.|Journal of Clinical Oncology|2020Cited by 177
Interval between planning and frameless stereotactic radiosurgery for brain metastases: are our margins still accurate?Charlotte Bronnimann, V. Vendrely, A. Huchet et al.|Neuro-Oncology Practice|2019Cited by 7